These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38238041)
21. Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L J Nucl Med; 2022 Apr; 63(4):560-566. PubMed ID: 34326127 [No Abstract] [Full Text] [Related]
22. Heinzel A; Boghos D; Mottaghy FM; Gaertner F; Essler M; von Mallek D; Ahmadzadehfar H Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1054-1062. PubMed ID: 30697649 [TBL] [Abstract][Full Text] [Related]
23. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions. Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422 [TBL] [Abstract][Full Text] [Related]
24. Extended therapy with [ Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927 [TBL] [Abstract][Full Text] [Related]
28. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy. Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376 [TBL] [Abstract][Full Text] [Related]
29. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [ Fanti S; Briganti A; Emmett L; Fizazi K; Gillessen S; Goffin K; Hadaschik BA; Herrmann K; Kunikowska J; Maurer T; MacLennan S; Mottet N; Murphy DG; Oprea-Lager DE; O'Sullivan JM; Oyen WJG; Rouvière O; Sartor O; Stenzl A; Van Poppel H; Walz J; Witjes W; Bjartell A Eur Urol Oncol; 2022 Oct; 5(5):530-536. PubMed ID: 35697600 [TBL] [Abstract][Full Text] [Related]
30. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [ Buteau JP; Martin AJ; Emmett L; Iravani A; Sandhu S; Joshua AM; Francis RJ; Zhang AY; Scott AM; Lee ST; Azad AA; McJannett MM; Stockler MR; Williams SG; Davis ID; Hofman MS; Lancet Oncol; 2022 Nov; 23(11):1389-1397. PubMed ID: 36261050 [TBL] [Abstract][Full Text] [Related]
31. Prognostic importance of prostatic specific antigen response in patients who received Lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. Soydal C; Araz M; Urun Y; Nak D; Ozkan E; Kucuk NO Q J Nucl Med Mol Imaging; 2021 Sep; 65(3):282-286. PubMed ID: 31602963 [TBL] [Abstract][Full Text] [Related]
32. A VISION Substudy of Reader Agreement on Kuo PH; Yoo DC; Avery R; Seltzer M; Calais J; Nagarajah J; Weber WA; Fendler WP; Hofman MS; Krause BJ; Brackman M; Kpamegan E; Ghebremariam S; Benson T; Catafau AM; Kendi AT J Nucl Med; 2023 Aug; 64(8):1259-1265. PubMed ID: 37230533 [TBL] [Abstract][Full Text] [Related]
33. The role of Ga Erdogan M; Sengul SS; Cetin B; Avcı M; Yagci S; Ozkoç I; Barikan DE; Yildiz M Ann Nucl Med; 2022 Jun; 36(6):562-569. PubMed ID: 35397091 [TBL] [Abstract][Full Text] [Related]
36. Clinical Translation and First In-Human Use of [ Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832 [TBL] [Abstract][Full Text] [Related]
37. Molecular imaging and biochemical response assessment after a single cycle of [ Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047 [No Abstract] [Full Text] [Related]
38. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. Pouliot F; Beauregard JM; Saad F; Trudel D; Richard PO; Turcotte É; Rousseau É; Probst S; Kassouf W; Anidjar M; Camirand Lemyre F; Bouvet GF; Neveu B; Tétu A; Guérin B BJU Int; 2022 Sep; 130(3):314-322. PubMed ID: 34674367 [TBL] [Abstract][Full Text] [Related]
39. Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Meyrick D; Gallyamov M; Sabarimurugan S; Falzone N; Lenzo N Target Oncol; 2021 May; 16(3):369-380. PubMed ID: 33687624 [TBL] [Abstract][Full Text] [Related]
40. Tc-99m PSMA and Lu-177 PSMA Theranostic Pair in a Patient of Metastatic Castration Resistant Prostate Cancer. Sheikh N; Younis MN; Mumtaz M; Shahid A J Pak Med Assoc; 2021 Nov; 71(11):2679-2682. PubMed ID: 34783763 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]